- Home
- BASE vs GYRE Comparison
BASE vs GYRE Comparison
Compare BASE & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BASE
- GYRE
- Stock Information
- Founded
- BASE 2011
- GYRE 2002
- Country
- BASE United States
- GYRE United States
- Employees
- BASE N/A
- GYRE N/A
- Industry
- BASE EDP Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BASE Technology
- GYRE Health Care
- Exchange
- BASE Nasdaq
- GYRE Nasdaq
- Market Cap
- BASE 1.0B
- GYRE 897.1M
- IPO Year
- BASE 2021
- GYRE N/A
- Fundamental
- Price
- BASE $24.27
- GYRE $7.34
- Analyst Decision
- BASE Hold
- GYRE
- Analyst Count
- BASE 16
- GYRE 0
- Target Price
- BASE $22.97
- GYRE N/A
- AVG Volume (30 Days)
- BASE 1.9M
- GYRE 253.7K
- Earning Date
- BASE 06-03-2025
- GYRE 08-12-2025
- Dividend Yield
- BASE N/A
- GYRE N/A
- EPS Growth
- BASE N/A
- GYRE N/A
- EPS
- BASE N/A
- GYRE 0.02
- Revenue
- BASE $214,662,000.00
- GYRE $100,643,000.00
- Revenue This Year
- BASE $12.17
- GYRE $21.04
- Revenue Next Year
- BASE $14.28
- GYRE $89.64
- P/E Ratio
- BASE N/A
- GYRE $93.77
- Revenue Growth
- BASE 12.76
- GYRE N/A
- 52 Week Low
- BASE $12.78
- GYRE $6.11
- 52 Week High
- BASE $25.16
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- BASE 75.69
- GYRE 36.76
- Support Level
- BASE $24.08
- GYRE $7.14
- Resistance Level
- BASE $24.50
- GYRE $7.80
- Average True Range (ATR)
- BASE 0.51
- GYRE 0.49
- MACD
- BASE 0.31
- GYRE -0.06
- Stochastic Oscillator
- BASE 87.54
- GYRE 0.48
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.